Our result revealed that HCC patients with sorafenib-resistant have higher ATP1B3 expression compared to HCC patients with sorafenib-sensitive, suggesting that ATP1B expression is associated with sorafenib-resistant in HCC patients. The gene discussed is ATP1B3; the disease is hepatocellular carcinoma.